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A B S T R A C T
Rationale and objective: Incidence of thyroid cancer (TC) is rapidly increasing worldwide, but little is
known about the TC burden in Central and South America (CSA). We describe the geographic patterns and
trends of TC by sex in CSA.
Methods: We obtained regional- and national-level incidence data from 48 population-based cancer
registries in 13 countries and nationwide cancer deaths from the WHO mortality database for
18 countries. We estimated world population age-standardized incidence rates (ASRs) and age-
standardized mortality rates (ASMRs) per 100,000 person-years. We calculated ASRs by histological
subtype. We estimated the annual percentage change (EAPC) to describe time trends.
Results: Between CSA countries, TC incidence and mortality rates varied from 8-fold to 12-fold and from
2-fold to 5-fold, respectively. In 2003–2007, the highest TC ASRs in females and males were in Ecuador
(16.0 and 3.5, respectively), Brazil (14.4 and 3.4), Costa Rica (12.6 and 2.1) and Colombia (10.7 and 2.5).
The highest ASMRs were in Ecuador, Colombia, Mexico, Peru and Panama (0.68–0.91 in females and 0.41–
0.48 in males). Papillary TC was the most commonly diagnosed histological subtype, following the same
incidence pattern as overall TC. In Argentinean, Brazilian, Chilean and Costa Rican females TC incidence
increased by 2.2–17.9% annually, and papillary TC increased by 9.1–15.0% annually, while mortality
remained stable between 1997 and 2008. In males, trends in TC were stable.
Conclusion: TC occurred more frequently in females than in males. The overall high incidence and low
mortality of TC suggest identiﬁcation of subclinical disease due to improved detection methods.
ã 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd. This is an open access article
under the CC BY-NC-ND IGO 3.0 license (https://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
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Thyroid cancer (TC) is the most common malignancy of the
endocrine system; however, thyroid tumors represent only 1% of
the global cancer burden [1]. On the basis of current estimates, TC
was the eighth most frequently diagnosed cancer among females
worldwide, accounting for approximately 3.5% of all the newly
diagnosed cancer cases in 2012, whereas in males TC was less
common, representing <1% of the total number of all new cancer
diagnoses. Global mortality due to this malignancy is low and
accounts for <1% of all cancer-related deaths estimated to occur in$ This is an Open Access article published under the CC BY NC ND 3.0 IGO license
which permits users to download and share the article for non-commercial
purposes, so long as the article is reproduced in the whole without changes, and
provided the original source is properly cited. This article shall not be used or
reproduced in association with the promotion of commercial products, services or
any entity. There should be no suggestion that IARC endorses any speciﬁc
organisation, products or services. The use of the IARC logo is not permitted. This
notice should be preserved along with the article’s original URL.
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creativecommons.org/licenses/by-nc-nd/3.0/igo/).females and males in 2012 [2]. In Central and South America (CSA),
TC was the sixth most common cancer diagnosed among females,
representing 4% of all new cancer diagnoses expected to occur in
2012; in males TC was rare, accounting for <1% of the total number
of cancer diagnoses. TC mortality in CSA accounted for about 0.5%
of all cancer-related deaths in both sexes in 2012 [2].
TC incidence has been steadily increasing over the past few
decades in Europe, North America, and some Asian and South
American countries. In most countries, however, mortality rates
have remained stable or declined, yet increases have been
described in the United States, the United Kingdom and Australia
in more recent years [3–5]. Increases in TC incidence have largely
been due to the rise in the incidence of papillary TC, the histological
subtype with the most favorable prognosis, and the detection of
mainly small tumors [6–10], while the rates of other histological
types (follicular, medullary and anaplastic TC) remained rather
stable [6–8,11]. Declines in TC incidence and mortality may reﬂect
better diagnosis, management and treatment of this disease [5].
A few studies on TC conducted in the CSA region – mainly in
Costa Rica and some South American countries – have shown an
important geographic variation in incidence rates between. This is an open access article under the CC BY-NC-ND IGO 3.0 license (https://
M.S. Sierra et al. / Cancer Epidemiology 44S (2016) S150–S157 S151registries within the same country and in mortality rates between
countries [5,12]. Nevertheless, an exhaustive evaluation of inci-
dence patterns by histological subtype in CSA is still lacking. The
purpose of this study was to describe the most current incidence
and mortality patterns and trends from TC by sex in the CSA region,
including a distinction by histological subtype, in order to
understand how TC incidence has changed over time and what
factors may explain the changes. We interpret our results in the
light of established TC risk factors that could further increase our
understanding of the etiology of this disease in CSA and potentially
add relevant information for future hypothesis testing studies on
TC in this geographical area.
2. Methods
The present analysis includes thyroid cancer (C53), as coded by
the 10th edition of the International Classiﬁcation of Diseases for
Oncology (ICD-10). The data sources and methods are described in
detail in an earlier article in this supplement issue. In brief, we
obtained regional- and national-level incidence data from 48
population-based cancer registries in 13 countries and nationwide
cancer deaths from the World Health Organization mortality
database for 18 countries. We estimated age-standardized inci-
dence rates (ASRs) and age-standardized mortality rates (ASMRs)
per 100,000 person-years using the direct method and the world
standard population [13,14]. We estimated national ASRs by
aggregating the data from the available cancer registries using a
weighted average of local rates. Registries that provided formal
consent to use data by individual year of diagnosis for 10-years
were included in the time-trend analysis (Table 1). To describe
incidence and mortality time trends, we calculated the estimated
annual percentage change (EAPC) for the most recent 10-year
period using the method proposed by Esteve et al. [15]. All of the
EAPCs were tested for equality to zero by using the corresponding
standard errors. We considered EAPCs statistically signiﬁcant if
P  0.05. We conducted the data analysis in Stata version 12.1
(StataCorp) [16].
We also estimated ASRs by the four major histological subtypes
as used in Cancer Incidence in Five Continents (CI5) volume X [17]:
follicular (8290, 8330–8335), papillary (8050, 8260, 8340–8344,
8350, 8450–8460), medullary (8345, 8510–8513) and anaplastic
(8020–8035).
3. Results
3.1. Incidence
During the most recent period evaluated, TC was one of the ﬁve
most common cancers in females in Ecuador, Brazil, Bolivia,
Colombia, Costa Rica, Cuba, and Mexico, and one of the ten most
frequent cancers in other countries in CSA. In males TC was among
the 25 most commonly diagnosed cancers in the region. Through
the CSA region, the incidence of TC varied by over 8-fold in females
and by approximately 12-fold in males. In 2003–2007, females had
4–6 times higher incidence rates of TC than males, although
statistically signiﬁcant differences between sexes were only seen
in eight countries (Table 2). Ecuador, Brazil, Costa Rica, andTable 1
Countries included in the analysis of time trends.
Country Name of registries included 
Argentina Bahia Blanca 
Brazil Aracaju, Fortaleza, Goiania, Sao Paulo 
Chile Valdivia 
Costa Rica National registry Colombia had the highest ASRs in the region (ranging from 10.7 to
16.0 in females and from 2.1 to 3.5 in males) and Bolivia, El
Salvador, and Mexico had the lowest rates (1.9–4.9 in females and
1.2 in males) (Table 2).
3.2. Mortality
TC mortality ranked among the 12th–22nd most common
causes of cancer deaths in CSA in both sexes (except in females
from El Salvador). There was a 5-fold and 2-fold geographic
variation in mortality rates in females and males, respectively. The
female-to-male mortality ratio was 1.1–3:1, with no statistically
signiﬁcant differences observed (Table 2). In females, the highest
ASMRs in the region were in Ecuador, Colombia, Mexico and Peru
(range 0.7–0.9) and the lowest was in Belize (0.17). In males the
highest ASMRs were in Ecuador, Mexico and Panama (0.4–0.5) and
the lowest rates in Brazil, El Salvador, and Guatemala (rates of 0.20)
(Table 2).
3.3. Time trends
Trends in TC incidence in females steadily increased in
Argentina (1998–2007), Costa Rica (1985–2007), Brazil (1997–
2006) and Chile (1997–2008) from the mid-1990s, while mortality
rates remained rather stable (Figs. 1 and 2). In females, TC was one
of the fastest growing cancer diagnoses in Argentina, Costa Rica,
and Brazil in the last 10-year period (EAPCs: 17.9%, 8.5%, and 6.2%,
P < 0.05, respectively). In Chilean females, TC incidence increased
over time but the increase did not reach statistical signiﬁcance. In
males, TC incidence and mortality rates were fairly stable over
time, although some non-statistically signiﬁcant increases in
incidence were observed in Brazil and Costa Rica (Figs. 1 and 2).
3.4. Incidence rates by major histological types
Approximately 80% of all TCs diagnosed in 2003–2007 in the
CSA region were papillary carcinomas, 10% were follicular
carcinomas, and 5.8% were unspeciﬁed. Females had higher ASRs
than males across all histological subgroups. The female-to-male
ratios were in the range of 4–10:1 for papillary, 2–5:1 for follicular,
1–2:1 for medullary (except in El Salvador), and 1–2:1 for
anaplastic TC (Table 3). Ecuador, Brazil, Costa Rica, and Colombia
had the highest papillary TC ASRs in the region (ranging from 8.9 to
13.6 in females and from 1.8 to 2.7 in males) and Bolivia and El
Salvador had the lowest rates (1.0–2.1 in females and <0.5 in
males). Similar distributions in ASRs were observed in CSA for
follicular, medullary and anaplastic TCs, except for Brazilian
females who had the highest rates of follicular (1.4) and medullary
TC (0.2), and Colombian females who had the highest rate of
anaplastic TC (0.2) (Table 3).
Fig. 3 shows trends in TC incidence by histological subtype and
sex. In females, papillary TC incidence steadily increased in
Argentina, Costa Rica, Brazil and Chile from the mid-1990s. From
1997 to 2008, the incidence of papillary TC in females rose annually
on average by 15.0% in Argentina, 10.5% in Brazil, 9.4% in Chile, and
9.1% in Costa Rica (P-values < 0.05). In males, incidence of papillary
TC showed an increased trend in Brazil and Costa Rica; however,Period % of the population covered
1993–2007 0.8
1997–2006 8.0
1993–2008 2.2
1985–2007 100.0
Table 2
Age-standardized incidence and mortality rates (per 100,000) from thyroid cancer in Central and South America, all ages.
Country (Period) Sex INCIDENCE MORTALITY
Cases Crude Rate ASR (W) F:M Ranka Deaths Crude Rate ASR (W) F:M Ranka
CENTRAL AMERICA
Belize (2003–07) F 1 0.1 0.2 21
M 0 – – 22
Costa Rica (2003–07) F 1343 12.8 12.6 6.1c 5 56 0.5 0.5 1.3 19
M 215 2.0 2.1 18 33 0.3 0.4 20
Cubab (2004–07) F 158 9.8 7.7 5.2d 5 148 0.66 0.4 1.3 21
M 28 1.7 1.5 20 83 0.37 0.3 19
El Salvadorb (1999–03) F 235 1.6 1.9 6.3 6 46 0.3 0.3 1.5 17
M 33 0.3 0.3 16 21 0.15 0.2 21
Guatemala (2003–07) F 94 0.29 0.5 2.5 15
M 34 0.11 0.2 18
Mexicob (2006–10) F 836 4.7 4.9 4.0 5 1899 0.64 0.9 1.8 14
M 184 1.1 1.2 17 804 0.29 0.5 20
Nicaragua (2003–07) F 55 0.4 0.6 3 12
M 17 0.13 0.2 17
Panama (2003–07) F 32 0.4 0.5 1.3 18
M 29 0.36 0.4 17
SOUTH AMERICA
Argentinab (2003–07) F 748 5.8 5.5 4.0 10 550 0.56 0.4 1.3 20
M 168 1.4 1.4 22 307 0.32 0.3 20
Boliviab (2011) F 35 2.6 2.7 4.5 5
M 8 0.6 0.6 18
Brazilb (2003–07) F 9254 15.0 14.4 4.2c 4 1763 0.37 0.4 2.0 20
M 1724 3.1 3.4 17 814 0.18 0.2 19
Chileb (2003–07) F 198 8.9 8.2 5.7d 7 312 0.76 0.6 1.5 19
M 34 1.5 1.4 20 147 0.36 0.4 19
Colombiab (2003–07) F 1135 11.3 10.7 4.2c 5 771 0.71 0.8 2.0 17
M 216 2.4 2.5 18 279 0.26 0.4 20
Ecuadorb (2003–07) F 780 15.2 16 4.5 3 268 0.8 0.9 1.8 13
M 143 3.0 3.5 14 128 0.38 0.5 16
French Guyanab
(2003–08)
F 27 5.4 6.6 4.6d 9
M 6 1.2 1.4 23
Paraguay (2003–07) F 62 0.43 0.6 2.0 16
M 32 0.21 0.3 19
Perub (2001–05) F 734 7.6 7.5 4.4d 8 376 0.56 0.7 2.3 14
M 147 1.6 1.7 20 135 0.2 0.3 19
Suriname (2003–07) F 5 0.4 0.4 17
M 0 – – 22
Uruguay (2005–07) F 412 8.0 6.8 4.2d 8 37 0.72 0.4 1.0 20
M 91 1.9 1.6 21 26 0.54 0.4 20
Venezuela (2003–07) F 321 0.48 0.6 2.0 18
M 155 0.23 0.3 19
ASR (W), age-standardized (world population) rate per 100,000; M, males; F, females; F:M, female-to-male rate ratio, males as the reference category; italics, rates estimated
with fewer than ten cases which should be interpreted carefully.
a Rank across cancer types, based on highest ASR excluding: All sites but C44 and All sites.
b Incidence rates were estimated using data from regional cancer registries.
c Poisson regression P  0.05.
d Poisson regression P  0.10.
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Trends in incidence rates of follicular, medullary and anaplastic TC
remained rather stable over time (EAPC P-values > 0.05, data not
shown).
4. Discussion
TC incidence and mortality rates in CSA showed a remarkable
geographic variation (incidence varied by 8-fold in females and
about 12-fold in males, while mortality varied by 5-fold in females
and 2-fold in males) which is likely to reﬂect differences in disease
ascertainment, diagnosis and treatment, healthcare access, as well
as improvements in death certiﬁcation [5,12,18]. The highest
incidence rates observed in both females and males in the CSA
region (Ecuador, Brazil, Costa Rica and Colombia) were comparable
to those in countries of very high human development, such as the
United States and Canada [17]. Although TC mortality rates in the
region were relatively low for both sexes (<1.0), the highestmortality rates in females observed in Ecuador, Mexico, Colombia
and Peru were also among the highest in the world, surpassed only
by Kuwait (1.0), and were three times higher than those among
females in the United States (0.3) for 2003–2007 [19]. Similarly, the
highest mortality rates in males observed in Ecuador, Panama and
Mexico were among the highest in the world and were comparable
to rates in Hungary, Israel, and Estonia (all with rates of 0.5) for the
same period [19]. The lowest incidence and mortality rates in the
region in both sexes were observed in El Salvador, Bolivia and
Mexico and in Belize and El Salvador, respectively. These
geographic variations in TC rates are, again, likely to reﬂect
differences in disease ascertainment, diagnosis and treatment,
healthcare access, and improvements in the registration of deaths
[5,12,18,20]. In the United States, for example, the incidence of TC
varied considerable between northeast and southeast regions;
such variations seem to correlate positively with the density of
endocrinologists, general surgeons, and the use of cervical
ultrasonography [20].
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incidence and mortality rates than males (female-to-male
ratios = 4–6:1 and 1.1–3:1, respectively, for 2003–2007). This sex
disparity has been described previously [5,9,11,21–24]. Although
sex hormones are thought to be responsible for the relatively high
TC incidence among females, particularly in their reproductive
years [25,26], the relationship between sex hormones and TC
remains unclear [25–27]. Evidence from autopsy studies shows
that the prevalence of papillary thyroid microcarcinomas (<10 mm
diameter) is similar between sexes, but in clinical cases this
prevalence is higher in women than in men (83% versus 17%),suggesting that women may undergo clinical investigations for
thyroid disease more frequently than men [28]. In the last two
decades, the increase in the number of TC cases in high-income
countries is probably due to diagnostic changes as a result of the
introduction of neck ultrasonography in the 1980s and the use of
ﬁne-needle aspiration biopsy in the late 1980s which allowed the
detection and histological examination of very small nodules. In
2003–2007, 51–83% and 19–56% of all TC cases diagnosed among
women and men (80 years), respectively, were attributed to
diagnostic changes (except in Japan: 30% and 3%). Countries with
the largest incidence rates of TC in both sexes had the highest
Table 3
Age-standardized incidence rates (ASRs) (world population) per 100,000 person-years of thyroid cancer: microscopically veriﬁed cases by the four major histological types in
Central and South America (all ages).
Country (Period) Sex Papillary Follicular Medullary Anaplastic
Cases ASR Cases ASR Cases ASR Cases ASR
CENTRAL AMERICA
Costa Ricaa (2003–07) F 1167 10.9 67 0.7 20 0.2 14 0.1
M 160 1.5 23 0.2 7 0.1 4 0.1
Cubaa (2004–07) F 132 6.6 10 0.5 3 0.1 1 0.0b
M 21 1.2 4 0.2 0 – 1 0.0b
El Salvadora (1999–03) F 118 1.0 17 0.1 2 0.0b 9 0.1
M 14 0.1 3 0.0b 4 0.0b 1 0.0b
Mexicoa (2005–10) F 856 4.2 59 0.3 2 0.0b 17 0.1
M 172 1.0 13 0.1 1 0.0b 7 0.0b
SOUTH AMERICA
Argentinaa (2003–07) F 587 4.4 59 0.4 15 0.1 9 0.1
M 116 1.0 10 0.1 6 0.1 7 0.1
Boliviaa (2011) F 28 2.1 2 0.1 1 0.1 1 0.1
M 6 0.5 0 – 0 – 2 0.1
Brazila (2003–07) F 6429 9.9 864 1.4 147 0.2 49 0.1
M 1115 2.1 166 0.3 53 0.1 24 0.1
Chilea (2003–07) F 168 7.0 4 0.2 4 0.2 4 0.1
M 30 1.3 1 0.0b 1 0.0b 0 –
Colombiaa (2003–07) F 946 8.9 66 0.6 7 0.1 16 0.2
M 154 1.8 21 0.3 3 0.0b 6 0.1
Ecuadora (2003–07) F 670 13.6 33 0.8 9 0.2 5 0.1
M 112 2.7 12 0.4 3 0.1 1 0.0b
French Guyanaa (2003–07) F 20 4.9 4 1.0 1 0.2 1 0.5
M 4 1.0 0 – 0 – 0 –
Perua (2001–05) F 552 5.6 25 0.3 14 0.1 9 0.1
M 107 1.2 11 0.1 7 0.1 5 0.1
Uruguaya (2005–07) F 282 4.8 67 1.1 9 0.2 9 0.1
M 55 1.0 16 0.3 6 0.1 2 0.0b
F, females; M, males; Italics, rates estimated with fewer than 10 cases which should be interpreted carefully.
a Incidence rates were estimated using aggregated data from regional cancer registries.
b Rates below 0.05.
S154 M.S. Sierra et al. / Cancer Epidemiology 44S (2016) S150–S157proportion of cases attributed to diagnostic changes (i.e. Republic
of Korea, Australia, the United States) [29].
We observed remarkable increases in TC incidence rates over
time among females but not in males in Argentina, Brazil, Chile and
Costa Rica from 1997 to 2008. Steady increases in TC incidence in
both men and women have also been reported in several countries
and regions worldwide in the last few decades [5,9,11,22,30]. For
example, in Cali, Colombia, female TC has increased from 5.5 in
1962–1966 to 11.1 in 2003–2007 [24].
We did not detect statistically signiﬁcant changes in TC
mortality rates in Argentina, Brazil, Chile and Costa Rica in
1997–2008. However, La Vecchia et al. [5] reported declines in
female and male TC mortality rates for Argentina, Brazil, Chile, and
Costa Rica (females) when comparing rates from 2000 to 2010. The
discrepancy between the two studies could be related to differ-
ences in the periods analyzed.
Papillary TC was the most frequently diagnosed histological
type in the CSA region; the highest incidence rates of papillary TC
were in Ecuador, Costa Rica, Brazil and Colombia, which is
consistent with the overall TC incidence pattern. There was
relatively less geographic variation across the other histological
types; however, Brazilian females had the highest rates of follicular
and medullary TC, and Colombian females had the highest rate of
anaplastic TC. Trends in incidence rates of papillary TC followed the
same pattern as the overall TC incidence, with a steady increase in
incidence among females observed in Argentina, Costa Rica, Brazil
and Chile since the mid-1990s, whereas trends for other TC
subtypes were less obvious, probably because of the small number
of cases. Similar ﬁndings have been reported in Western Europe,
the United States, Israel, Japan, Australia and Canada [5,9]. These
results suggest that the increased incidence in overall TC inArgentina, Brazil, Chile and Costa Rica was driven mainly by the
increased incidence of papillary TC.
Along with medical surveillance, it is possible that the
remarkable geographic variation in TC rates observed across the
CSA region may be related to environmental and life-style changes
[3,5,21]. Although exposure to ionizing radiation, particularly in
childhood, is an established factor known to increase the risk of TC
[31,32], it accounts for a small fraction of the cases given the low
prevalence in the general population. Medical exposure to ionizing
radiation (computed tomography and nuclear medicine examina-
tions) has been suggested as a potential factor for the increasing
trends in thyroid cancer, as it is one of the fastest growing sources
of human radiation exposure in the recent years [29]. As
populations are increasingly being exposed to diverse sources of
radiation from medical diagnostics or treatment for benign or
malignant conditions, radiosensitive organs like the thyroid may
respond differently, particularly when they occur at different ages
(childhood versus adulthood) [33]. A recent case–control study
conducted in Connecticut, United States, showed that exposure to
any form of diagnostic radiography was associated with a 3-fold
increase in the risk of well-differentiated thyroid microcarcinomas
(tumor size 10 mm). In contrast, exposure to any form of
diagnostic radiography was not related to the risk of thyroid
tumors >10 mm [34].
Medical history of goiter or thyroid nodules are established risk
factors for TC in both women and men [31,35]. Iodine deﬁciencies
or excesses have been related to TC, although not consistently [36].
Iodine intake may inﬂuence the distribution of TC by histological
subtype, with follicular TC being more frequently found in iodine-
deﬁcient areas and papillary TC in areas with high iodine intake
[3,37–40]. We coincidentally observed high TC incidence rates in
.0
1
.1
1
10
10
0
1985 19 90 1995 2000 2005 2010
Papillary
.0
1
.1
1
10
10
0
198 5 1990 1995 20 00 2005 2010
Folli cular
.0
1
.1
1
10
10
0
1985 19 90 1995 2000 2005 2010
Medull ary
MaleFemale
.0
1
.1
1
10
10
0
198 5 1990 1995 20 00 2005 2010
Anap lastic
Ag
e-
st
an
da
rd
iz
ed
 in
ci
de
nc
e 
ra
te
s 
(lo
g 
sc
al
e)
 p
er
 1
00
,0
00
 p
er
so
n-
ye
ar
s
*Incidence rates wer e estimated using aggregated data from re gional can cer registries
Lines represent the (LOWESS=0.5) smoothed trend
Argentina* Brazil* Chile* Costa Rica
Fig. 3. Trends in thyroid cancer age-standardized incidence rates (per 100,000) by the four major histological types in Central and South America (all ages).
M.S. Sierra et al. / Cancer Epidemiology 44S (2016) S150–S157 S155Ecuador, Brazil, Costa Rica, and Colombia, and high mortality rates
in Ecuador, Colombia, Mexico, Panama and Peru, countries with
(past) history of goiter and iodine deﬁciency [41]; it is unclear,
however, how these two factors could have impacted the observed
TC rates. Harach et al. [38] conducted a study in the province of
Salta, Argentina, a population with history of iodine deﬁciency, to
investigate the relationship between changing concentrations of
potassium iodide during two different iodine prophylaxis periods
and the incidence of anaplastic TC. The incidence of anaplastic TC
decreased from 0.14 per 100,000 in 1960 (prior to prophylaxis) to
0.01 per 100,000 in 2010 (after prophylaxis) (P < 0.06). Such
decline in incidence could be explained by early detection due to
the establishment of primary healthcare centres in the area and the
use of ﬁne-needle aspiration cytology, which could have led to the
early detection of papillary or follicular TC. Therefore, iodineprophylaxis may not be the only explanation for the observed
decreased incidence of anaplastic TC [38].
Epidemiological evidence has linked anthropometric measures
(height and weight) with a moderately increased risk of TC,
particularly of papillary and follicular TC [42]. Increased body mass
index (BMI) has been associated with the risk of several cancers,
including TC, which may differ between sexes and populations
[42–46]. In Latin America (including the Caribbean),11% and 22% of
the TC cases estimated to occur in women and men, respectively, in
2012 were attributed to high BMI (25 kg/m2), suggesting a causal
relationship [47]. This is particularly important in CSA because the
prevalence of overweight/obesity has steadily increased since the
1990s [48], particularly among women and people living in urban
areas [49]. The increase in incidence of TC observed in the past
10 years appears to correspond with an increased prevalence of
S156 M.S. Sierra et al. / Cancer Epidemiology 44S (2016) S150–S157obesity among the most economically developed countries in the
region (Brazil, Chile, and Costa Rica), although this apparent
association also warrants further investigation.
4.1. Strengths and limitations
This study presents the most exhaustive analysis of TC rates in
the CSA region to date, including incidence data from 13 countries
(48 cancer registries) – more than the data published in the latest
volume of CI5 (eight countries, 22 cancer registries) [17] – and
includes mortality data from 18 countries. However, data patterns
should be interpreted with caution because it is necessary to
consider problems related to random variation owing to the
relatively small number of cases in some populations, particularly
for medullary and anaplastic TC. Rates could be inﬂuenced by
differences in detection and reporting of TC across countries and
registries within the region. With the exception of the national
cancer registries of Costa Rica and Uruguay, countrywide incidence
rates are represented by aggregated data from regional cancer
registries, which do not cover the entire country. Cancer registries
in CSA may differ in population coverage, completeness and data
quality, which depend on the maturity of the cancer registry, and
this could explain why some of the thyroid cancer rates observed in
Mexico, Bolivia and El Salvador were low. Unfortunately, data
regarding tumor size and stage is not systematically collected in
most cancer registries in the region, thus limiting further
evaluation of subclinical disease and stage at diagnosis. The
estimation of thyroid cancer mortality rates may be inﬂuenced by
the quality of national mortality. In some CSA countries, mortality
data may be considered of medium or low quality [50]. In general,
special attention must be paid while interpreting incidence or
mortality rates estimated using less than ten cases because they
may not be stable (i.e. Belize).
5. Conclusion
TC incidence and mortality rates varied considerably within
countries in Central and South America (8–12-fold and 2–6-fold,
respectively). Rates also varied by sex: females had 4–6 times
higher incidence rates and 1–3 times higher mortality rates than
males. The highest incidence rates observed in Ecuador, Brazil,
Costa Rica and Colombia were comparable to the incidence in
countries of very high human development. However, the highest
mortality rates observed in Ecuador, Mexico, Colombia, Panama
and Peru were among the highest in the world. The remarkable
geographic variation and sex disparity in TC rates observed across
the region may reﬂect differences in ascertainment, diagnosis,
treatment, and death certiﬁcation of this disease, as well as
healthcare access.
In the past decade, the incidence of TC rapidly increased in
Argentina, Brazil, Chile, and Costa Rica, while mortality rates
remained stable. The discrepancy between increased incidence
and stable mortality of TC may be due to the identiﬁcation of
indolent disease, shown by the higher increase in papillary TC
incidence as compared to other subtypes. Consequently, monitor-
ing of potential risk factors for TC, recording and describing
changes in diagnostic activities, and close examination of TC trends
could help elucidate the real burden of this disease in the CSA
region. There is a need for cancer registries to systematically collect
information on clinical stage and tumor size in order to evaluate
whether the increases in TC trends are due to over-diagnosis.
Future studies could shed light on whether the striking variation in
incidence within the region is reﬂective of the availability of
imaging services and/or to the identiﬁcation subclinical disease
(indolent tumors).Conﬂict of Interest
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